In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to toxicity, comorbidities, and the burden of repeated parenteral administration. US MM-6 (NCT03173092) enrolled transplant-ineligible patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Rifkin, Robert M., Girnius, Saulius K., Noga, Stephen J., Birhiray, Ruemu E., Kambhampati, Suman, Manda, Sudhir, Lyons, Roger M., Yimer, Habte A., Cherepanov, Dasha, Lloyd, Eric, Whidden, Presley, Richter, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509188/
https://www.ncbi.nlm.nih.gov/pubmed/37726298
http://dx.doi.org/10.1038/s41408-023-00912-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509188/
https://www.ncbi.nlm.nih.gov/pubmed/37726298
http://dx.doi.org/10.1038/s41408-023-00912-9

Ejemplares similares